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AbstrAct
Introduction To understand the puberty-related sex shift 
in the prevalence of asthma and rhinitis as single entities 
and as respiratory multimorbidities, we investigated if 
there is also a sex-specific and puberty-related pattern of 
their incidences.
Methods We used harmonised questionnaire 
data from 18 451 participants in five prospective 
observational European birth cohorts within 
the collaborative MeDALL (Mechanisms of the 
Development of Allergy) project. Outcome definitions 
for IgE-associated and non-IgE-associated asthma, 
rhinitis and respiratory multimorbidity (first 
occurrence of coexisting asthma and rhinitis) were 
based on questionnaires and the presence of specific 
antibodies (IgE) against common allergens in serum. 
For each outcome, we used proportional hazard 
models with sex–puberty interaction terms and 
conducted a one-stage individual participant data 
meta-analysis.
results Girls had a lower risk of incident asthma 
(adjusted HR 0.67, 95% CI 0.61 to 0.74), rhinitis 
(0.73, 0.69 to 0.78) and respiratory multimorbidity 
(0.58, 0.51 to 0.66) before puberty compared with 
boys. After puberty onset, these incidences became 
more balanced across the sexes (asthma 0.84, 
0.64 to 1.10; rhinitis 0.90, 0.80 to 1.02; respiratory 
multimorbidity 0.84, 0.63 to 1.13). The incidence sex 
shift was slightly more distinct for non-IgE-associated 
respiratory diseases (asthma 0.74, 0.63 to 0.87 before 
vs 1.23, 0.75 to 2.00 after puberty onset; rhinitis 
0.88, 0.79 to 0.98 vs 1.20, 0.98 to 1.47; respiratory 
multimorbidity 0.66, 0.49 to 0.88 vs 0.96, 0.54 to 
1.71) than for IgE-associated respiratory diseases.
Discussion We found an incidence ‘sex shift’ 
in chronic respiratory diseases from a male 
predominance before puberty to a more sex-balanced 
incidence after puberty onset, which may partly 
explain the previously reported sex shift in prevalence. 
These differences need to be considered in public 
health to enable effective diagnoses and timely 
treatment in adolescent girls.
IntroDuctIon
Meta-analyses of published results from 
cross-sectional studies suggested a sex shift 
in the prevalence of allergic rhinitis with and 
without concurrent asthma around puberty. 
The prevalence shifted from a clear male 
predominance in childhood towards a female 
predominance in adolescence.1 2 Similar asso-
ciations were found by individual participant 
data (IPD) meta-analyses combining harmo-
nised data from large European birth cohorts 
collaborating in MeDALL (Mechanisms of 
the Development of Allergy): boys were more 
likely than girls to have higher prevalence of 
Key messages
 ► We examined whether the sex-specific incidence of 
asthma, rhinitis and respiratory multimorbidity dif-
fered before and after puberty onset.
 ► A meta-analysis of longitudinal birth cohorts showed 
a sex shift from higher incidence in boys before pu-
berty towards a rather sex-balanced incidence after 
puberty onset.
 ► The elevated risk of asthma and rhinitis incidences 
in teenage girls should lead to more consideration of 
a sex-specific and age-specific focus on diagnosis 
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asthma, rhinitis and respiratory multimorbidity (defined 
as concurrent asthma and rhinitis) before puberty; after 
the onset of puberty, a sex shift towards a sex-balanced 
estimated prevalence was found.3
Reasons for the considerable sex shift in the prevalence 
of allergic diseases remain unclear. Asthma and rhinitis 
are chronic diseases that can develop throughout child-
hood but may not persist into school age or adolescence. 
Prevalence may be affected by remission and by different 
sex-specific incidence patterns. Therefore, we aimed to 
investigate whether the sex-specific incidence patterns of 
asthma and rhinitis as single entities as well as their co-oc-
currence change with the onset of puberty.
MethoDs
study design and setting
This study was carried out as part of the MeDALL project, 
a European research initiative for a better understanding 
of the development of asthma and allergy. Participating 
birth cohorts were longitudinal, observational and popu-
lation-based. For the present analyses, IPD from the five 
oldest birth cohorts participating in the MeDALL project 
(BAMSE: Swedish abbreviation for Children, Allergy, 
Milieu, Stockholm, Epidemiology, PIAMA: Prevention 
and Incidence of Asthma and Mite Allergy, GINIplus: 
German Infant Nutritional Intervention-Program, LISA: 
Lebensstil, Immunsystem, Allergien and MAS: Multizen-
trische Allergie Studie4) from three European countries 
(Sweden, the Netherlands and Germany) with follow-up 
assessments up to 20 years of age were used. Data from the 
five cohorts were combined by consistent harmonisation 
rules and processes,5 6 while data from the most recent 
follow-up were derived from a common harmonised 
MeDALL Core Questionnaire for four of the five birth 
cohorts.7 A detailed description of the overall MeDALL 
collaboration8 9 and the inclusion and exclusion criteria 
of the birth cohorts for the current analysis have been 
reported previously.3
Definition of primary outcomes
Incident asthma, rhinitis and respiratory multimorbidity 
were our primary outcomes. If five or more consecutive 
years of follow-up of the primary outcome data were 
missing, the data were censored at the last available 
follow-up.
Definition of asthma and rhinitis
Asthma was defined as a positive answer to at least two of 
the three following questions:
 ► ‘Has your child (/Have you) ever been diagnosed by 
a doctor as having asthma?’ (yes/no).
 ► ‘Has your child (/Have you) had wheezing or whis-
tling in your chest at any time in the last 12 months?’ 
(yes/no).
 ► ‘Has your child (/Have you) taken any medication 
for asthma (including inhalers, nebulisers, tablets 
or liquid medicines) or breathing difficulties (chest 
tightness, shortness of breath) in the last 12 months?’ 
(yes/no).
Rhinitis was defined according to the International 
Study of Asthma and Allergies in Childhood (ISAAC)10 
as a positive response to the following question:
 ► ‘Has your child (/Have you) had problems with 
sneezing, or a runny, or blocked nose when s/he did 
not have a cold or flu in the past 12 months?’ (yes/
no).
For each question the wording ‘Has your child’ stems 
from the parental questionnaire, and the wording ‘Have 
you’ stems from the adolescent questionnaire.
Definition of incident asthma and incident rhinitis
Incident asthma and rhinitis were rated ‘positive’ if there 
was:
 ► A positive first time ever assessment of the disease at 
the current follow-up.
Incident asthma and rhinitis were rated ‘negative’ if:
 ► The assessment of the disease was negative at the 
current follow-up and
 ► The assessment of the disease was not positive at any 
earlier follow-up.
Definition of incident respiratory multimorbidity
Incident respiratory multimorbidity was rated ‘positive’ 
if there was:
 ► A positive first time ever assessment of both rhinitis 
and asthma at the current follow-up.
Incident respiratory multimorbidity was rated ‘nega-
tive’ if:
 ► The assessment of rhinitis and/or asthma was nega-
tive at the current follow-up and
 ► The assessment of both asthma and rhinitis together 
was not positive at an earlier follow-up.
Definition of secondary outcomes
Allergic sensitisation assessed by specific IgE
All included birth cohorts had information on specific 
antibodies against common aeroallergens, that is, dog, 
cat, house dust mite and birch pollen, which were meas-
ured as specific IgE in the serum. A participant had a 
positive allergic sensitisation status if at least one of the 
four specific IgE measurements was ≥0.7 kU/L serum. 
Accordingly, a participant had a negative allergic sensiti-
sation status if all of the specific IgE measurements were 
<0.7 kU/L.
The following were the six secondary outcomes:
 ► IgE-related and non-IgE-related asthma (defined 
as a positive incident asthma/questionnaire data in 
combination with a positive or negative sensitisation 
status/IgE data, respectively).
 ► IgE-related and non-IgE-related rhinitis (defined 
as a positive incident rhinitis/questionnaire data in 
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 ► IgE-related and non-IgE-related respiratory multi-
morbidity (defined as a positive incident respiratory 
multimorbidity/questionnaire data in combination 
with a positive or negative sensitisation status/IgE 
data, respectively).
If five or more consecutive years of follow-up of the 
secondary outcome data were missing, the data were 
censored at the last available follow-up. For these six 
secondary outcomes, questionnaire incident data were 
combined with either IgE data assessed at the same 
follow-up or with IgE data from the most recent available 
follow-up, and analyses were thus restricted to those with 
non-missing questionnaire incident and IgE data. Please 
see online supplementary table 5 for a general over-
view of available questionnaire and IgE data at different 
follow-ups.
Definition of the time-dependent covariable puberty
Participant puberty status was self-assessed by the vali-
dated Pubertal Development Scale (PDS), which is widely 
used in population studies, or available data covering 
information from the PDS using the items ‘body hair 
growth’, ‘voice change’ and ‘facial hair growth’ for boys, 
and the items ‘body hair growth’, ‘breast development’ 
and ‘menstruation’ for girls.11 Based on these items the 
dichotomous variable ‘onset of puberty’ (yes/no) was 
calculated. Absence of any signs of puberty was rated as a 
negative onset of puberty status, while mid-pubertal, late 
pubertal or postpubertal category scores were all summa-
rised as a positive onset of puberty status. Further details 
of this definition are presented elsewhere.3
Definition of confounder variables
The model was adjusted for the following previously iden-
tified variables: age (continuous), parental allergies, that 
is, one or both parents with self-reported rhinitis and/
or asthma (yes/no), maternal smoking during pregnancy 
(yes/no), and cohort.
statistical analyses
Data were analysed with SAS V.9.4 and R V.3.1.2 (R Foun-
dation for Statistical Computing). In all analyses the 
missing values were excluded list-wise. Baseline data and 
incidences of the primary and secondary outcomes were 
described as frequencies and percentages per age and 
sex for each cohort and in total.
We used one-stage IPD meta-analyses to combine the 
data from five European birth cohorts (BAMSE, PIAMA, 
GINIplus, LISA and MAS). Proportional hazard models 
including puberty as a time-dependent covariable with 
the average partial likelihood method for handling ties 
in the event times were used for analysing the data. 
Within each proportional hazard model for all primary 
and secondary outcomes, two adjusted HRs with 95% CIs 
were presented, one comparing boys versus girls before 
puberty onset, and one comparing them after puberty 
onset. P values were reported for the interaction term 
‘sex*puberty’, which reflects the sex-specific changes 
in outcome incidences before versus after puberty 
onset in the model. The present clinical questions and 
data analyses are post-hoc, and we consider the results 
to be hypothesis-generating rather than confirmatory. 
Therefore, all results, including p values, are consid-
ered exploratory and were not adjusted for any multiple 
testing. In defining the primary outcome, incidence was 
rated ‘missing’ if asthma and/or rhinitis were missing at 
the current follow-up. If the incidence was rated positive 
in an earlier follow-up, the participant was no longer at 
risk and was censored for the incidence calculation at the 
current follow-up.
Patient and public involvement
We did not include patients, only samples of healthy 
infants from the general population. Participants and 
the public were not involved in the development of the 
research question, outcome measures or study design. 
The individual birth cohort study teams inform their 
participants regularly about relevant new results of these 
long-term prospective studies, mainly via their study-spe-
cific websites.
results
basic characteristics of the five included birth cohorts
Five birth cohorts collaborating in the MeDALL project 
with 18 451 recruited participants in total were included. 
Due to dropouts, the available IPD for analyses of primary 
and secondary outcomes varied at different follow-ups. At 
most follow-ups the rate of dropouts was equal between 
sexes, and only at some follow-ups we found more male 
than female dropouts (see online supplementary table 
1). The included follow-up assessment time points were 
from 4 to 20 years of age. About half of the participants 
were male, and positive parental history of allergy ranged 
from 43% to 56% in the different cohorts. Across the 
three cohorts with data at age 10 years, 1.9% of male and 
13.6% of female participants reported signs of puberty 
at the 10-year follow-up. These percentages increased to 
over 90% at the 15-year and 16-year follow-ups for both 
boys and girls, respectively (table 1).
Incidence and sex shift of asthma
The incidence of asthma was lower for girls than for 
boys at preschool and early school-age follow-ups. The 
percentages decreased for both sexes over time (see 
online supplementary table 2). Before puberty onset, 
girls were at a considerably lower risk than boys for devel-
oping incident asthma (HR 0.67, 95% CI 0.61 to 0.74). 
After puberty onset, the difference was less distinct (girls 
vs boys; HR 0.84, 95% CI 0.64 to 1.10). The interac-
tion term ‘sex*puberty’ described a p=0.122 (figure 1). 
These findings were similar for IgE-associated asthma, 
whereas for non-IgE-associated asthma we found a more 
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edizin Berlin, M








pen Resp Res: first published as 10.1136/bmjresp-2019-000460 on 13 September 2019. Downloaded from 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pen Resp Res: first published as 10.1136/bmjresp-2019-000460 on 13 September 2019. Downloaded from 
Hohmann C, et al. BMJ Open Resp Res 2019;6:e000460. doi:10.1136/bmjresp-2019-000460 5
Open access
Figure 2 Adjusted HRs and 95% CIs for the risk of the 
incidence of IgE-associated and non-IgE-associated 
asthma, rhinitis and respiratory multimorbidity for boys 
versus girls before and after puberty onset. The presented 
results are based on analyses of n=10 320, n=10 331 and 
n=10 304 participants, respectively. aHR, adjusted HR.
Figure 1 Adjusted HRs and 95% CIs for the risk of the 
incidence of asthma, rhinitis and respiratory multimorbidity 
for boys versus girls before and after puberty onset. The 
presented results are based on analyses of n=14 245, n=14 
266 and n=14 233 participants, respectively. aHR, adjusted 
HR.
pronounced sex shift towards female predominance after 
puberty onset (HR 0.74, 95% CI 0.63 to 0.87 before vs 
1.23, 0.75 to 2.00 after puberty onset) (figure 2).
Incidence and sex shift of rhinitis
In follow-ups during preschool and early school age, 
rhinitis incidence was more frequently reported in boys 
than in girls. At the latest follow-up assessments, most 
cohorts had either similar or slightly higher rhinitis inci-
dences in girls compared with boys (see online supple-
mentary table 3).
Before puberty onset, girls were at a considerably lower 
risk than boys for incident rhinitis (HR 0.73, 95% CI 0.69 
to 0.78), whereas after puberty onset this lower risk was 
less distinct and almost sex-balanced (HR 0.90, 95% CI 
0.79 to 1.02): interaction term ‘sex*puberty’ p=0.005 
(figure 1). Incidences of IgE-associated and non-IgE-as-
sociated rhinitis differed considerably considering 
the effect of puberty onset: the male predominance 
remained almost identical before and after puberty onset 
for IgE-associated rhinitis, whereas for the incidence of 
non-IgE-associated rhinitis we found a sex switch from 
male to female predominance after puberty onset (HR 
0.88, 95% CI 0.79 to 0.98 before vs 1.20, 0.98 to 1.47 after 
puberty onset) (figure 2).
Incidence and sex shift of respiratory multimorbidity
Up to the age of 6 years, the incidence of respiratory 
multimorbidity was higher in boys than in girls in all 
cohorts. At the last follow-ups, most cohorts had an either 
similar or higher incidence of respiratory multimorbidity 
for girls compared with boys (see online supplementary 
table 4).
Before the onset of puberty, girls were at a consider-
ably lower risk than boys for incident respiratory multi-
morbidity (HR 0.58, 95% CI 0.51 to 0.66), and this effect 
was stronger than for asthma and rhinitis as single enti-
ties. After puberty onset, the risk for incident respiratory 
multimorbidity was sex-balanced (HR 0.84, 95% CI 0.63 
to 1.13; interaction term ‘sex*puberty’ p=0.02) (figure 1). 
Considering allergic sensitisation status, these findings 
were similar for the incidence of IgE-associated respi-
ratory multimorbidity and more pronounced towards a 
sex-balanced incidence for non-IgE-associated respira-
tory multimorbidity (HR 0.66, 95% CI 0.49 to 0.88 before 
vs 0.96, 0.54 to 1.71 after puberty onset) (figure 2).
DIscussIon
Main findings
Our longitudinal birth cohort meta-analyses using 
harmonised IPD specifically examined the sex-specific 
incidence in relation to puberty onset for common 
chronic allergic and respiratory conditions. Our results 
showed a sex shift from a male predominance before 
puberty towards a sex-balanced incidence after puberty 
onset for asthma and rhinitis as single entities and as a 
respiratory multimorbidity. These findings explain some 
of the previously described sex shifts in asthma and 
allergy prevalence from childhood to adulthood. After 
stratifying for allergic sensitisation, the sex-specific effect 
seemed stronger for non-IgE-associated conditions.
comparison with other studies
Similar to our findings, the Isle of Wight study found a 
male predominance for allergic rhinitis at 4 and 18 years. 
For non-allergic rhinitis the study reported no sex differ-
ence at 4 years but a female predominance at 18 years.12 
Observational population-based prevalence studies have 
been more common than incidence studies particularly 
for rhinitis and respiratory multimorbidity. A longitudinal 
Universitatsm
edizin Berlin, M








pen Resp Res: first published as 10.1136/bmjresp-2019-000460 on 13 September 2019. Downloaded from 
6 Hohmann C, et al. BMJ Open Resp Res 2019;6:e000460. doi:10.1136/bmjresp-2019-000460
Open access
British birth cohort study found the annual incidence of 
asthma and wheezing up to 16 years of age was higher in 
boys than in girls: 0.85% vs 0.58% on average per year. 
This effect reversed during follow-up at 17–23 years, when 
the incidence was considerably lower in boys than in girls: 
0.56% vs 0.94%.13 This finding suggested a prevalence sex 
shift at a slightly older age than that of our study partici-
pants. Given the age of effect reversal, it remains unclear 
if it is puberty onset-related. Puberty status was not specif-
ically evaluated in this UK birth cohort. The participants 
in the UK cohort were born in 1958, and the pubertal age 
has been decreasing over the past decades. A more recent 
cohort study from Canada stated a higher asthma inci-
dence for girls than for boys aged 12–18 years: 13.2% vs 
6.6% per 1000 person-years.14 A large Dutch cohort study 
based on medical records from a health database found 
an asthma incidence of 6.7 per 1000 person-years for chil-
dren and adolescents aged 5–18 years. They confirmed 
a sex shift in asthma incidence at the age of 13, with a 
male predominance before and a female predominance 
thereafter.15 Another Dutch study found a sex shift with 
more girls than boys reporting asthma at the age of 16. 
However, an association with the assessed pubertal status 
could not be confirmed.16 Individuals were found to have 
an increased risk of asthma if they reported an early but 
not a normal or late puberty onset.17 A lack of informa-
tion about early, normal or late puberty onset, as well 
as not taking into account the differentiation between 
IgE-associated and non-IgE-associated asthma, could 
account for some of the differences in the reported study 
results. Two recent systematic reviews of cross-sectional 
studies reported a sex-related shift for rhinitis prevalence 
with and without respiratory comorbidity from a male 
predominance in childhood towards a female predomi-
nance among adolescents.1 2 Our study adds to previous 
knowledge by examining incidence data in rhinitis and 
respiratory multimorbidity, the effect of puberty status, 
and a differentiation of IgE versus non-IgE-association 
for all three health outcomes. We were able to show that 
in the examined cohorts, puberty onset played a consid-
erable role in a shift from male predominance towards 
a more sex-balanced incidence of asthma, rhinitis and 
respiratory multimorbidity while controlling for age.
The incidence of asthma, rhinitis and respiratory multi-
morbidity varied between the cohorts in our combined 
analyses. Potential explanations include differences 
in the recruitment procedures, climatic regions (from 
Scandinavia to Southern Germany) and/or degree of 
urbanisation of the study areas (from urban to mixed 
urban-rural). Differences in assessment methods among 
the included cohorts have been minimised as the specific 
questions have been previously harmonised (based on 
the ISAAC questions) and underwent a further harmoni-
sation process for the latest assessment in adolescence.7 10 
Therefore, we consider the outcome and puberty data 
across the included cohorts to be comparable.
In line with our results, an elevated risk of adult-onset 
non-IgE-associated asthma in women has been previously 
reported.18 Various reasons for the observed increased 
risk of asthma and rhinitis in women after puberty 
have been discussed. Contributing factors may include 
sex-specific and age-related anatomical differences of 
the lung.19 Considering puberty and the postpubertal 
stage, there is strong evidence that the sex hormones 
oestrogen and progesterone influence the development 
and outcome of asthma. However, the question of which 
hormones have protective effects or increase the risk of 
developing allergy and asthma is not fully understood.19 
Women generally show stronger immune responses than 
men, which makes them potentially more vulnerable to 
autoimmunity and allergy. A suppressive effect of andro-
gens on group 2 innate lymphoid cells is supposed have a 
protective effect for allergic asthma in men after puberty 
onset.20
strengths and limitations
For this analysis, we aimed to focus on asthma, rhinitis 
and respiratory multimorbidity incidence data as these 
have relevant public health implications. An increased 
incidence in adolescence emphasises the need for a raised 
awareness for early diagnosis and treatment of formerly 
healthy female subjects. To date, incident asthma cases 
are less likely to be diagnosed in adolescence than in 
childhood. At 16 years, girls reported uncontrolled 
asthma more often but fewer doctors’ diagnoses and they 
were prescribed fewer medications than boys.21 As the 
prevalence of a disease is determined by its incidence and 
remission, prospectively collected longitudinal data to 
better understand the interplay of incidence and remis-
sion would be of interest in the future.
Among the strengths of the current study is the prospec-
tively collected longitudinal data from five different 
European population-based cohorts. Furthermore, we 
were able to include IPD from over 18 000 European 
birth cohort participants for the pooled analyses rather 
than performing ‘traditional’ meta-analyses combining 
already published effect estimates. Our approach aimed 
to minimise heterogeneity between the cohorts by 
harmonising the individual data a priori, where neces-
sary. The construction of a common database, thanks to 
a close trustful collaboration between the research teams, 
has led to a unique data source of European birth cohorts. 
The pooled data set has more statistical power than the 
individual cohort data sets and allows examination of less 
common (sub)phenotypes or exposures. This is the first 
longitudinal birth cohort evaluation of the incidence of 
asthma and rhinitis as single entities and as respiratory 
multimorbidities in relation to the puberty status of birth 
cohort participants.
Several limitations should be considered while inter-
preting the current study results. The five included Euro-
pean cohort studies are not representative of the general 
population of their countries. However, to a certain 
degree, they represent regional, mainly urban popula-
tions from where they were recruited.
Universitatsm
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Four out of five cohorts provided the latest follow-up 
for age 14–16 years and only one cohort for 20 years of 
age. Many girls at age 14–16 years were already in puberty 
at earlier follow-ups. Almost all participants were cate-
gorised as being at least in puberty, and many partici-
pants, especially the girls, had completed puberty by the 
last available follow-up. However, this cannot be inter-
preted as a long-term postpubertal observation period. 
Therefore, possible long-term effects of puberty-related 
hormone exposure cannot be evaluated with our sample 
and have to be subject to future investigations of these 
cohorts.
Another possible limitation of longitudinal studies 
such as birth cohorts is the systematic and unsystematic 
dropouts, resulting in lower participation rates and a 
possible bias over the time course. However, as this may 
influence the magnitude of the incidence estimates, we 
have no clear indication of a systematic sex-related loss of 
participants (see online supplementary table 1).
Our definition of incidence could not always be 
restrained to 1 year, which would have been desirable. 
Among the cohorts, time intervals between the follow-up 
assessments differed. The longest interval was 5 years. 
Even if the participants were asked for the occurrence 
of symptoms within the past 12 months, it could not be 
excluded that the condition might have already devel-
oped at an earlier time point within the time frame 
without a follow-up. This has to be considered for the 
definition of the onset of puberty. However, the cohorts 
all started with 100% prepubertal children, and we were 
eventually able to detect the onset of puberty in 96% of 
all participants. Lacking the exact timing of the onset of 
puberty might be negligible as it may not influence our 
results considerably. The variables of age and puberty 
onset are highly related. We aimed to disentangle these 
two variables by controlling for age while puberty was the 
time-dependent covariable.
conclusIons
Our IPD meta-analyses showed an incidence ‘sex shift’ in 
chronic respiratory diseases from males to females after 
puberty onset, which may partly explain the previously 
and more commonly reported prevalence ‘sex shift’. The 
observed sex shift, especially for non-IgE-related inci-
dences of the diseases, suggests sex-specific and puber-
ty-specific underlying mechanisms. Our results stress the 
importance of raising alertness among clinicians for inci-
dent cases of respiratory diseases in adolescent girls for 
effective detection and timely treatment.
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